Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.